Table 3.
Multivariable models of the association of selected patient characteristics with progression-free survival and overall survival in patients with and without renal impairment treated with idecabtagene vicleucel.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.